Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts Skeptical About Ability Of Korean Government To Draw Investors To Risky R&D Fund

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Investors and analysts are voicing skepticism about the Korean government's ability to successfully draw enough investors into a KRW2 trillion ($1.7 billion) R&D fund to help local companies develop innovative new drugs
Advertisement

Related Content

Korean Health Minister Could Enlist Special Prosecutor To Fight Kickbacks By Drug Makers
New Pricing System Could Deal A Blow To South Korea's Generic-Dependent Companies
Korean Government Announces Joint Fund To Beef Up Local Pharma Industry
Korean Government Announces Joint Fund To Beef Up Local Pharma Industry
Advertisement
UsernamePublicRestriction

Register

SC074106

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel